Westlake BioPartners is a Los Angeles area-based venture capital firm focused on incubating and building life sciences companies with entrepreneurs who have the potential to bring transformative therapies to patients. For more information, please visit www.westlakebio.com.

Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. Our platform approach integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity.

Member of Compensation CommitteeNeurogastrx, Inc. is a privately held, late clinical-stage biopharmaceutical company that is focused on identifying and developing therapies for patients suffering from serious gastrointestinal (GI) diseases.

Member of Compensation Committee, Nominating and Governance Committee, Lead Director (IPO in 2021)Impel Pharmaceuticals Inc. is a Seattle based commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for central nervous system disorders.

Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for novel radiotherapeutics. The company’s platform technology uses small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are overexpressed on these tumors. This small molecule technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. Spun out of Crinetics (Nasdaq: CRNX) in 2021 and financed by 5AM Ventures and Frazier Healthcare, Radionetics is advancing a pipeline that currently consists of multiple lead drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets.

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm's lead program is focused on the highly validated, genetically-defined target, HSD17B13.There is extensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on these novel insights into the biologic activity of HSD17B13, Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein.

Member Compensation CommitteeMagnetic Insight has pioneered magnetic particle imaging (MPI), a new diagnostic and monitoring technology that transforms medical imaging. MPI provides unique information not available from current structural and metabolic imaging captured by CT, MRI, and nuclear medicine. MPI offers what no other modality can: the ability to directly monitor costly cell therapy cancer treatments to inform clinical decision making. Having started in the preclinical space by selling small animal products to leading universities worldwide, Magnetic Insight is now scaling up MPI technology for clinical use.

Founded in 2002, 5AM Ventures is a leading venture capital firm focused on building next-generation life science companies. Based in San Francisco and Boston, 5AM takes a hands-on approach to investing and company building, often going beyond traditional board roles to leverage our diverse team of scientists, clinicians, drug developers and executives throughout a company’s life. For more information, please visit www.5amventures.com.

Member Audit Committee, Compensation CommitteePortal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for chronic diseases. Portal’s needle-free delivery technology is derived from research at MIT and enables the administration of high viscosity biologic drugs with less discomfort and without the anxiety of handling needles. Real time tracking and reporting sets a new standard for monitoring adherence and potentially improving patient outcomes.

Member of Audit Committee (IPO in 2022)CinCor was acquired by AstraZeneca for up to $1.8B in Jan 2023:https://www.cincor.com/node/8071/pdfCinCor is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases. Baxdrostat is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. Baxdrostat has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure.

Member Audit and Compensation CommitteesAcquired by Smith & Nephew in 2019Ceterix® Orthopaedics is singularly focused on meniscal preservation and is dedicated to providing patients every opportunity to maintain the natural health and stability of their knee. The company develops tools that help surgeons repair many of the tears that currently remain untreated or are treated by meniscectomy (meniscus removal), a procedure associated with increased risk of arthritis or total knee replacement later in life. The Ceterix NovoStitch® Plus Meniscal Repair System provides surgeons with the unique ability to repair horizontal, radial, root and other complex tears. Based in Fremont, Calif., the company is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures.

Initial Public Offering in 2018Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, a investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, and for CRN04894, an investigational, oral ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Healthcare investment professional at Versant Ventures, a healthcare venture capital firm founded in 1999 with offices in North America and Europe

Healthcare investment professional at Split Rock Partners, a venture capital firm founded in 2005 with $575 million under management.

Analyst, Associate and Senior Associate at PTV Healthcare Capital in Houston and Austin, TX.